Association between hepatitis B virus infection and HLA-DRB1 genotyping in Shaanxi Han patients in northwestern China

被引:46
作者
Yang, G.
Liu, J. [1 ]
Han, S.
Xie, H.
Du, R.
Yan, Y.
Xu, D.
Fan, D.
机构
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Digest Dis, State Key Lab Canc Biol, Xian, Peoples R China
[2] Fourth Mil Med Univ, Dept Epidemiol, Xian, Peoples R China
来源
TISSUE ANTIGENS | 2007年 / 69卷 / 02期
关键词
genetic association; hepatitis B virus; human leukocyte antigen; Shaanxi Chinese; susceptibility;
D O I
10.1111/j.1399-0039.2006.00744.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 [细胞生物学]; 090102 [作物遗传育种];
摘要
Hepatitis B virus (HBV) infection is a major public health problem worldwide. The mechanism of susceptibility to chronic persistent HBV infection is not well clarified, while the outcome of HBV infection mainly depends on the host immune response. Human leukocyte antigen (HLA) class II molecule is an integral component of the immune response on which majority of host genetic studies have concentrated. Many different HLA class II alleles have been demonstrated to play roles in HBV infection. In this study, the association between HBV infection and HLA-DRB1 alleles in Han individuals in northwestern China was studied for the first time. Two hundred and fifty Shaanxi Han individuals were categorized into three different groups: the HBV-infected patient group (n = 108), the spontaneously cleared control group (n = 108) and the unexposed group (n = 34). DRB1*04, DRB1*09, DRB1*12 and DRB1*15 were the most common genotypes in all the groups. The allele frequencies of HLA-DRB1*03 [10.6% of HBV-infected patients vs 3.7% of spontaneously cleared controls, odds ratios (OR) =3.10, Pc =0.008, P < 0.05] and HLA-DRB1*07 (17.6% of HBV-infected patients vs 9.3% of spontaneously cleared controls, Pc =0.016, OR =2.09, P < 0.05) were markedly higher in the HBV-infected group. But the allele frequencies of HLA-DRB1*15 (6.9% of HBV-infected patients vs 13.4% of spontaneously cleared controls Pc =0.039, OR =0.48, P < 0.05) were obviously lower than that of the spontaneously cleared controls. The above data indicate that HLA-DRB1*03 and HLA-DRB1*07 are related to susceptibility to chronic HBV infection, and DRB1*15 is negatively related to persistence to chronic HBV infection among people in northwestern China. Similar results were got for DRB1*03 and 15 alleles between the HBV-infected patients (n = 108) and 46 HBV seronegative spouses of the HBV patients, who were high-risk group for HBV infection. The above results suggest that host HLA class II gene is an important factor in determination of the outcome of HBV infection.
引用
收藏
页码:170 / 175
页数:6
相关论文
共 36 条
[1]
Association between hepatitis B virus infection and HLA-DR type in Korea [J].
Ahn, SH ;
Han, KH ;
Park, JY ;
Lee, CK ;
Kang, SW ;
Chon, CY ;
Kim, YS ;
Park, K ;
Kim, DK ;
Moon, YM .
HEPATOLOGY, 2000, 31 (06) :1371-1373
[2]
Amarapurpar D N, 2003, J Assoc Physicians India, V51, P779
[3]
HEPATITIS AND AUSTRALIA ANTIGEN - AUTOSOMAL RECESSIVE INHERITANCE OF SUSCEPTIBILITY TO INFECTION IN HUMANS [J].
BLUMBERG, BS ;
FRIEDLAE.JS ;
WOODSIDE, A ;
SUTNICK, AI ;
LONDON, WT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1969, 62 (04) :1108-&
[4]
HLA-A, -B and -DR antigen frequencies of the London Cord Blood Bank units differ from those found in established bone marrow donor registries [J].
Brown, J ;
Poles, A ;
Brown, CJ ;
Contreras, M ;
Navarrete, CV .
BONE MARROW TRANSPLANTATION, 2000, 25 (05) :475-481
[5]
Campbell Edward S., 2002, Human Immunology, V63, pS92, DOI 10.1016/S0198-8859(02)00650-X
[6]
In vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulin G production by HBcAg-specific CD4+ Th1-type T-cell clones in a hu-PBL-NOD/SCID mouse model [J].
Cao, TH ;
Meuleman, P ;
Desombere, I ;
Sällberg, M ;
Leroux-Roels, G .
JOURNAL OF VIROLOGY, 2001, 75 (23) :11449-11456
[7]
Chen SH, 2002, LC GC N AM, V20, P164
[8]
Cheng Yuan-qiao, 2003, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V20, P247
[9]
Cotrina M, 1997, Gastroenterol Hepatol, V20, P115
[10]
Diepolder HM, 1998, CLIN EXP IMMUNOL, V113, P244